The Haemophilia Academy is led by a distinguished Faculty of haemophilia experts from around the world.
The Haemophilia Academy is led by a distinguished Faculty of haemophilia experts from around the world.
Claude Négrier was head of the Haematology Department at Hôpital Louis Pradel in Lyon, France and Director of the Haemophilia Comprehensive Care Centre at this institution until the end of last year. He is currently Emeritus Professor of Haematology at the university of Lyon.
Professor Négrier has authored more than 160 peer-reviewed publications and acts as a reviewer for different journals including Blood, The Journal of Thrombosis and Haemostasis and Haemophilia, for which he is a member of the editorial board.
Professor Négrier’s research interests focus on molecular and cellular biology of factor VIII and factor IX, clinical evaluation of therapeutic modalities in patients who have developed an inhibitor and clinical utility of surrogate markers. In addition, he has a keen interest in the current and future approaches for treating patients with haemophilia, including innovative replacement and non-replacement molecules as well as gene therapy.
Victor Blanchette is Medical Director of the Paediatric Thrombosis and Haemostasis Programme in the Division of Haematology/Oncology at the Hospital for Sick Children, Toronto, and Medical Director of the SickKids-Caribbean Pediatric Cancer and Blood Disorders Initiative (SCI). He is also Professor of Pediatrics at the University of Toronto, Canada, where he is a Senior Associate Scientist in the Research Institute and a Clinician Investigator in the Department of Paediatrics.
Dr Blanchette received his medical training at the University of Cambridge and St Bartholomew’s Hospital in the United Kingdom. His postgraduate medical training included a paediatric residency at Johns Hopkins Hospital in the USA and a fellowship in paediatric haematology/oncology at McMaster University Medical Centre in Hamilton, Canada.
His research interests are in the area of inherited and acquired bleeding disorders of children. He is Director of the Paediatric Haemophilia Comprehensive Care Programme at the Hospital for Sick Children, and is a member of the Factor Prophylaxis Subcommittee of the Association of the Hemophilia Clinic Directors of Canada (AHCDC).
Dr Blanchette is Chair of the Canadian Paediatric Thrombosis and Hemostasis Network and a founding member of an Intercontinental Immune Thrombocytopenic Purpura (ITP) Study Group. He is Chair of the International Prophylaxis Study Group (the IPSG).
Dr Blanchette is an elected fellow of the Royal College of Physicians and Surgeons of the United Kingdom.
Roseline d’Oiron is a Clinician Investigator and Associate Director at the Reference Centre for Haemophilia and Other Congenital Rare Bleeding Disorders, Congenital Platelets Disorders and von Willebrand Disease at Bicêtre Hospital AP-HP – University Paris XI, Le Kremlin–Bicêtre, France. She is also responsible for Specialist training for the master’s degree in haematology at University Paris VII.
Dr d’Oiron graduated as a medical doctor from UFR Broussais-Hôtel-Dieu, University Paris VI, and completed her speciality training with master’s degrees in haematology, immunology, immunopathology, and transfusion medicine from UFR Saint-Antoine, University Paris VI.
Her research interests are principally in the area of haemophilia in both children and adults (especially molecular mechanisms of haemophilia A, inhibitors, immune tolerance, mild/moderate haemophilia, carrier issues and prophylaxis) and Glanzmann’s thrombasthenia.
Dr d’Oiron has served as member of the steering committee of the national FranceCoag Network on bleeding disorders and continues to serve as advisor to the working group on inhibitors in this registry. She is currently a member of the expert panel of the Glanzmann’s Thrombasthenia Registry (GTR). With the National Federation of Patients, she has developed an outreach program dedicated to women from families with haemophilia. Dr d’Oiron is also an elected member of the executive committee of the European Association for Haemophilia and Allied Disorders (EAHAD).
Keith Hoots joined the National Heart, Lung and Blood Institute of the U.S. National Institutes of Health (NIH) as Director, Division of Blood Diseases and Resources in January, 2009. In this role he directs the NIH extramural grant research programme for haematological diseases, which funds researchers across the U.S. and around the world.
The Division has three major branches targeting research: Hemostasis and Thrombosis; Blood Diseases (haemoglobinopathies, white blood cell disorders and anaemias); and Transfusion and Cell Therapies (transfusion medicine, bone marrow transplantation, stem cell therapies and biorepository). Prior to joining NIH, Dr Hoots was an academic haematologist at the University of Texas-M.D. Anderson Cancer Center and the University of Texas Medical School at Houston.
Dr Hoots gained his degree in medicine from the University of North Carolina and completed a fellowship at the Division of Pediatric Hematology/Oncology, Department of Pediatrics at the same institution. His clinical interests are principally in children with haemophilia and related conditions, and in people with haemophilia with HIV or cancer. Dr Hoots has published over 150 peer-reviewed articles and has also authored numerous books and book chapters on haemophilia and related conditions. He serves on the editorial boards of a number of haematological and general medical journals.
In 2000, Dr Hoots was named fellow of the American Heart Association and the Council on Arteriosclerosis, Thrombosis, and Vascular Biology. He has been recognised by the American National Hemophilia Foundation for his outstanding service to the bleeding disorders community.
Stacy Croteau is a paediatric haematologist and clinical investigator at Boston Children’s Hospital and an Assistant Professor of Pediatrics at Harvard Medical School, where she specialises in bleeding and clotting disorders. Dr. Croteau is the Head of the Haemophilia/vWD programme at Boston Children’s Hospital and Medical Director for the Boston Hemophilia Center serving Boston Children’s Hospital and Brigham and Women’s Hospital.
She also serves as a Region I (New England) Medical Director for the national network of U.S haemophilia treatment centres (HTCs) for the Centers of Disease Control bleeding disorders surveillance project. Dr. Croteau currently serves at the principle investigator for several industry-sponsored and investigator-initiated clinical trials on hemophilia and other bleeding and clotting disorders. She has published numerous original research and review articles in peer-reviewed journals and presents nationally and internationally on a broad spectrum of bleeding disorder topics for both medical professionals as well as the bleeding disorders community.
Professor Margareth Ozelo is Director of the WFH International Haemophilia Training Centre (IHTC) at the University of Campinas (UNICAMP) in Campinas, São Paulo, Brazil. She received her medical degree (1994), specialist training in haematology and transfusion medicine (1994-1997), and PhD (2004) from Unicamp before undertaking a postdoctoral fellowship in David Lillicrap’s laboratory, at Queen’s University in Kingston, Ontario, Canada (2006–2009).
Professor Ozelo also works closely with the Brazilian federal government in developing and improving the haemophilia and inherited coagulopathies policy in Brazil. She is also very active in developing and promoting the haemophilia care in Latin America. Under her leadership of the Hemophilia Comprehensive Care Unit at Hemocentro UNICAMP in Campinas, Brazil, the centre became a WFH International Hemophilia Training Centre and has trained doctors, nurses, physiotherapists, and laboratory technologists from Brazil, and many countries especially from Latin America.
Professor Ozelo is involved with several research projects, including inherited platelet disorders, gene therapy for haemophilia, risk factors for inhibitor development, immune tolerance induction, and the and the MSK-MADE (Measuring, Analyzing, Disseminating and Educating in Brazil): a Novo Nordisk Haemophilia Foundation project (2011–14).
Professor Ozelo was elected to the Novo Nordisk Haemophilia Foundation Council in 2012.
Christopher Ludlam is Emeritus Professor of Haematology and Coagulation Medicine at the University of Edinburgh and former Director of the Haemophilia and Thrombosis Centre at the Royal Infirmary of Edinburgh.
His initial research was in the field of platelet proteins and assessing their value in patients with platelet disorders, and in thromboembolic conditions. Over the past 25 years, however, his major activities have been towards promoting the development of safe therapeutic products for haemophilia. His studies have included setting up surveillance for potential pathogens and other adverse events, along with developing treatment options for those who become infected.
Professor Ludlam has been Chairman of the UK Haemophilia Centre Doctors’ Organisation and President of the British Society of Haemostasis and Thrombosis. He has served as Chairman or a member of national committees advising on the provision of haemophilia and coagulation services in the UK and Europe. He is a past President of the European Association for Haemophilia and Allied Disorders.
Professor Lillicrap is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University, Kingston, Canada. Since 2000, he has been the recipient of a Canada Research Chair in Molecular Hemostasis. In 2013, he was elected to the Fellowship of the Royal Society of Canada.
He is the Chair of the Research Committee of the World Federation of Hemophilia (WFH) and is a member of the Medical Advisory Board of the WFH. He served a three-year term as the Chairperson of the International Society on Thrombosis and Haemostasis’ Scientific and Standardization sub-committee (SSC) on von Willebrand Factor, and is the immediate Past-Chair of the Society’s SSC. He was recently elected to a five-year term as a Member of the ISTH Council. From 2008 to 2014, he served as an Associate Editor of the journal Blood, and he is also a member of the editorial board of the British Journal of Haematology.
Professor Lillicrap’s research program relates to molecular aspects of the hemostatic system, with particular emphasis on novel therapeutic approaches and immunological complications of hemophilia A, and the genetics, biology and pathobiology of von Willebrand factor.
Johannes Oldenburg is Director of the Institute of Experimental Haematology and Transfusion Medicine and the Haemophilia Centre at the University Clinic in Bonn, Germany. He completed his specialty training in transfusion medicine at the University of Bonn and in medical genetics at the University of Wuerzburg.
Prior to his current position, he served as Assistant Professor and leader of the research group ‘Molecular Haemostasis’ at the Institute of Experimental Haematology and Transfusion Medicine at the University of Bonn, and as Head of the Departments of Immune Haematology and Molecular Haemostasis at the Institute of Transfusion Medicine and Immune Haematology in Frankfurt.
Professor Oldenburg’s research interests include the molecular genetics of blood coagulation factors with an emphasis on haemophilia and vitamin K pathways. He has published more than 250 articles in these fields. Professor Oldenburg also serves as a reviewer for many professional journals in the field of haemostasis or genetics. He is or has been a member of the editorial boards of several journals in the field including Blood, The Journal of Thrombosis and Haemostasis and Haemophilia.
Professor Oldenburg is a member of the Blood Committee for the German Ministry of Health. He was the recipient of the GEFFRUP Award from the University Clinic Bonn (1992), the Johann Lukas Schönlein Award (1996), the GTH Alexander Schmidt Award (2002), the GTH Professor Landbeck Award 2004, the Paul Martini Award (2005), the ISTH Shirley Johnson Memorial Plenary Lecture 2007 and the ISTH Biennial Investigator Recognition Award 2007.
Jørgen Ingerslev was formerly Professor in Haemostasis and Thrombosis at Aarhus University, Denmark, and a Haemophilia Centre Director at the National Haemophilia Center of Western Denmark. This centre provides services to younger patients with venous thromboembolism and occlusive cerebrovascular disease.
Professor Ingerslev had degrees in internal medicine and clinical biochemistry, and his scientific interests have mainly focused on haemophilia, von Willebrand disease, factor VIII/von Willebrand factor and the clinical and biochemical aspects of bleeding in haemophilic patients with inhibitors. Recent developments focused on the dynamics of fibrin formation and thrombin generation in haemophilia and other bleeding disorders.
He was a member of the American Society of Haematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH), and served terms as Chairman and co-Chair for the Factor VIII and Factor IX subcommittee. He also served as Secretary of the European Association for Haemophilia and Allied Disorders (EAHAD).